Výsledky vyhledávání
- 1.MACHOVA POLAKOVA, K.G; ALBEER, A.; POLIVKOVA, V.; KRUTSKA, M.; VLCANOVA, K.; CURIK, N.; FABARIUS, A; KLAMOVA, H.; ET AL. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia. 2024, vol. 38, no. 2, s. 318-325. ISSN 0887-6924.
- 2.CURIK, N.; LAZNICKA, A.; POLIVKOVA, V.; KRIZKOVA, J.; POKORNA, E.; SEMERAK, P.; SUCHANKOVA, P.; BURDA, P.; HOCHHAUS, A.; MACHOVA POLAKOVA, K. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024, ,in press. ISSN 0887-6924.
- 3.MAHON, F.-X.; PFIRRMANN, M.; DULUCQ, S.; HOCHHAUS, A.; PANAYIOTIDIS, P.; ALMEIDA, A.; MAYER, J.; HJORTH-HANSEN, H.; JANSSEN, J.J.W.M.; MUSTJOKI, S.; MARTINEZ-LOPEZ, J.; VESTERGAARD, H.; EHRENCRONA, H.; MACHOVÁ POLÁKOVÁ, K.; ET AL. European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: fanalysis and novel prognostic factors for treatment-free remission. Journal of clinical oncology. 2024, in press,. ISSN 0732-183X.
- 4.ŽÁČKOVÁ, D.; SEMERÁD, L.; FABER, E.; KLAMOVÁ, H.; STEJSKAL, L.; BĚLOHLÁVKOVÁ, P.; KARAS, M.; CMUNT, E.; ČERNÁ, O.; PROCHÁZKOVÁ, J.; ČIČÁTKOVÁ, P.; KVETKOVÁ, A.; HORŇÁK, T.; SKOUMALOVÁ, I.; SRBOVÁ, D.; ŠÁLEK, C.; BUFFA, D.; VOGLOVÁ, J.; JURČEK, T.; FOLTA, A.; JEŽÍŠKOVÁ, I.; ŽIŽKOVÁ, H.; MACHOVÁ POLÁKOVÁ, K.; ET AL. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia. 2024, in press,. ISSN 0887-6924.
- 5.BENESOVA, B.; DE SANTIS, S.; POLIVKOVA, V.; PECHERKOVA, P.; KRIZKOVA, K.; SUCHANKOVA, P.; MONALDI, C.; KLAMOVA, H.; SRBOVA, D.; ZIZKOVA, H.; HOCHHAUS, A.; SOVERINI, S.; MACHOVA POLAKOVA, K.G Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. American journal of hematology. 2024, vol. 99, no. 4, s. 759-762. ISSN 0361-8609.
- 6.VRÁBLOVÁ, L.; DIVOKÝ, V.; KOŘALKOVÁ, P.; MACHOVÁ POLÁKOVÁ, K.; ET AL. Deep molecular response achieved with chemotherapy, dasatinib and interferon α in patients with lymphoid blast crisis of chronic myeloid leukaemia. International journal of molecular sciences. 2023, vol. 24, no. 3, art. no. 2050. ISSN 1422-0067.
- 7.CROSS, N.C.P; ERNST, T.; BRANFORD, S,; CAYUELA, J.-M.; DEININGER, M.; FABARIUS, A.; KIM, D.D.H.; MACHOVA POLAKOVA, K.; ET AL. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023, vol. 37, no. 11, s. 2150-2167. ISSN 0887-6924.
- 8.WHITE, H.E.; SALMON, M.; ALBANO, F.; ANDERSEN, C.S.A.; BALABANOV, S.; BALATZENKO, G.; BARBANY, G.; CAYUELA, J.-M.; CERVEIRA, N.; COCHAUX, P.; COLOMER, D.; CORIU, D.; DIAMOND, J.; DIETZ, C.; DULUCQ, S.; ENGVALL, M.; FRANKE, G.N.; GINEIKIENE-VALENTINE, E.; GNIOT, M.; GÓMEZ-CASARES, M.T.; GOTTARDI, E.; HAYDEN, C.; HAYETTE, S.; HEDBLOM, A.; ILEA, A.; IZZO, B.; JIMENEZ-VELASCO, A.; JURCEK, T.; KAIRISTO, V.; LANGABEER, S.E.; LION, T.; MEGGYESI, N.; MEŠANOVIĆ, S.; MIHOK, L.; MITTERBAUER-HOHENDANNER, G.; MOECKEL, S.; NAUMANN, N.; NIBOUREL, O.; OPPLIGER-LEIBUNDGUT, E.; PANAYIOTIDIS, P.; PODGORNIK, H.; POTT, C.; RAPADO, I.; ROSE, S.J.; SCHÄFER, V.; TOULOUMENIDOU, T.; VEIGAARD, C.; VENNIKER-PUNT, B.; VENTURI, C.; VIGNERI, P.; VORKINN, I.; WILKINSON, E.; ZADRO, R.; ZAWADA, M.; ZIZKOVA, H.; MÜLLER, M.C.; SAUSSELE, S.; ERNST, T.; MACHOVA-POLAKOVA, K.; HOCHHAUS, A.; CROSS, N.C.P. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022, vol. 36, no. 7, s. 1834-1842. ISSN 0887-6924.
- 9.SOVERINI, S.; DE SANTIS, S.; MARTELLI, M.; MONALDI, C.; CASTAGNETTI, F.; GUGLIOTTA, G.; PAPAYANNIDIS, C.; MANCINI, M.; BRUNO, S.; VENTURI, C.; MACHOVA POLAKOVA, K.; ET AL. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022, vol. 36, no. 9, s. 2250-2260. ISSN 0887-6924.
- 10.SALMON, M.; WHITE, H.E.; ZIZKOVA, H.; GOTTSCHALK, A.; MOTLOVA, E.; CERVEIRA, N.; COLOMER, D.; CORIU, D.; FRANKE, G.N.; GOTTARDI, E.; IZZO, B.; JURCEK, T.; LION, T.; SCHÄFER, V.; VENTURI, C.; VIGNERI, P.; ZAWADA, M.; ZUNA, J.; HOVORKOVA, L.; KOBLIHOVA, J.; KLAMOVA, H.; STASTNA MARKOVA, M.; SRBOVA, D.; BENESOVA, A.; POLIVKOVA, V.; ZACKOVA, D.; MAYER, J.; ROEDER, I.; GLAUCHE, I.; ERNST, T.; HOCHHAUS, A.; MACHOVA POLAKOVA, K.; CROSS, N.C.P. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022, vol. 36, no. 7, s. 1879-1886. ISSN 0887-6924.